Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Every story we pull is tagged to the disease it’s about — so you can filter to your condition and read only what matters.
Showing news related to
when lupus strikes twice pancreatitis and nephritis in an overlap syndrome a rare multisystem flare
Original title: “When Lupus Strikes Twice: Pancreatitis and Nephritis in an Overlap Syndrome - A Rare Multisystem Flare.”
pregnancy and lactation during anifrolumab treatment in systemic lupus erythematosus
Original title: “Pregnancy and lactation during anifrolumab treatment in systemic lupus erythematosus.”
clinical features and outcomes of patients with anti neutrophil cytoplasmic antibody positive systemic lupus erythematosus from a single center retrospective study
Original title: “Clinical features and outcomes of patients with anti-neutrophil cytoplasmic antibody-positive systemic lupus erythematosus from a single-center retrospective study.”
progression of skin limited pediatric onset discoid lupus erythematosus to diagnosis of systemic lupus erythematosus results of a multicenter retrospective cohort study
Original title: “Progression of skin-limited pediatric-onset discoid lupus erythematosus to diagnosis of systemic lupus erythematosus: results of a multicenter, retrospective cohort study.”
bone marrow infiltration of large b cell lymphoma with clinical manifestations similar to systemic lupus erythematosus a case report
Original title: “[Bone marrow infiltration of large B-cell lymphoma with clinical manifestations similar to systemic lupus erythematosus: A case report].”
The therapy works by genetically modifying cells to enable the body’s own immune system to recognise and attack problem cells I’m taking every gift that UCLH and that trial has given me, and I’m running with it.” · The new study enrolled nine patients aged 12 to 65 with active, severe disease who had not responded to multiple treatments for lupus. ... Senior Clinical Practice Facilitator Nicole Prescott administering breakthrough treatment to patient Katie Tinkler for lupus at University College London Hospital in London (PA) “These findings provide early evidence that CAR T-cell therapy may be able to reset the immune system and drive meaningful clinical improvements after a single treatment. “Although these are still early days, the results mark an important step forward in exploring how cellular therapies could transform the treatment of autoimmune diseases.” ... In the new NHS trial, led by University College London Hospitals NHS Foundation Trust (UCLH) and University College London (UCL), five out of six patients with severe lupus went into remission within a few months of receiving CAR-T (PA) A new NHS trial, spearheaded by University College London Hospitals NHS Foundation Trust (UCLH) and University College London (UCL), saw five out of six severe lupus patients achieve remission within months of CAR-T treatment. Over an average 11-month follow-up, rapid improvements in disease markers were observed, including stabilisation or enhancement of kidney function previously damaged by lupus. The CAR-T in the trial was obecabtagene autoleucel (obe-cel), developed by UCL spinout firm Autolus Therapeutics. Obe-cel is designed to target and deplete CD19-positive B cells, which play a central role in lupus. Katie Tinkler was forced to give up her job as a fitness instructor because of debilitating pain and fatigue caused by the severe lupus she has had since she was 20. Lupus caused her to suffer very swollen and painful joints, kidney damage that meant she was close to needing dialysis, lung and heart disease, and a tendency to develop blood clots.
Original title: “Groundbreaking NHS immune therapy sees lupus patients go into remission”
single cell sequencing in systemic lupus erythematosus
Original title: “Single-cell sequencing in systemic lupus erythematosus.”
clinicopathological characteristics and renal outcomes of iga nephropathy in systemic lupus erythematosus a case report and systematic literature review
Original title: “Clinicopathological characteristics and renal outcomes of IgA nephropathy in systemic lupus erythematosus: a case report and systematic literature review.”
dna engineered dual signal biomimetic fusion vesicles for rapid evaluation of systemic lupus erythematosus
Original title: “DNA-Engineered Dual-Signal Biomimetic Fusion Vesicles for Rapid Evaluation of Systemic Lupus Erythematosus.”
diffuse splenic calcifications in systemic lupus erythematosus a case based review
Original title: “Diffuse splenic calcifications in systemic lupus erythematosus: a case-based review.”
targeting type i interferon in lupus panniculitis a case based systematic literature review
Original title: “Targeting type I interferon in lupus panniculitis: a case-based systematic literature review.”
epidemiology and prognosis of childhood lupus nephritis in the afro descendant population of the french overseas departments of america
Original title: “Epidemiology and prognosis of childhood lupus nephritis in the Afro-descendant population of the French Overseas Departments of America.”
Greater flexibility for people with systemic lupus erythematosus
Original title: “Saphnelo approved in the US for subcutaneous self‑administration”
Leading Beeline Medicines’ pipeline is afimetoran, which is in Phase 2 development for systemic lupus erythematosus with data expected later this year.
Original title: “BMS makes a Beeline, bringing 5 assets to biotech's $300M precision immunology debut”
real world longitudinal data on the impact of hydroxychloroquine blood level monitoring on lupus outcomes results of a prospective longitudinal cohort study
Original title: “Real-world Longitudinal Data on the Impact of Hydroxychloroquine Blood Level Monitoring on Lupus Outcomes: Results of a Prospective Longitudinal Cohort Study.”
tofacitinib versus baff inhibitor in mild to moderate systemic lupus erythematosus a real world study based on cstar cohort
Original title: “Tofacitinib versus BAFF inhibitor in mild to moderate systemic lupus erythematosus: a real-world study based on CSTAR cohort.”
Tyvaso, a marketed PAH therapy from United Therapeutics, continued to show potential in another lung condition. Elsewhere, Aurinia inked an acquisition and Lilly built its case for Ebglyss.
Original title: “United rises on IPF data; Biogen scores positive lupus data and an approval”
William Blair hailed a positive readout in cutaneous lupus erythematosus as a turning point for Biogen, while RBC Capital analysts called the results “another derisking step” for the company’s immunology and inflammation pipeline.
Original title: “Biogen's Lupus Drug Reduces Disease Activity, Further Deresking I&I Pipeline”
psychosis in patients with systematic lupus erythematosus a systematic literature review and meta analysis
Original title: “Psychosis in patients with systematic lupus erythematosus: A systematic literature review and meta-analysis.”
rare and unique case of quadricuspid aortic valve in a patient with triple valve disease and lupus
Original title: “A rare and unique case of quadricuspid aortic valve in a patient with triple valve disease and lupus.”